ライフサイエンスコーパス: drop out

1 r VEGF, suggesting AT rarefaction (capillary drop out).

2 zed to stop IFN treatment and 25 to taper (1 drop-out).

3 d, 2 developed Richter transformation, and 1 dropped out).

4 patients without ARI, and 18 individuals who dropped out).

5 retrieval and look for systematic DNA strand drop out.

6 ly missing, and collecting data on intent to drop out.

7 s showed dose-dependent FeSO(4)-induced cone drop out.

8 evidence of PCR issues such as large allele drop out.

9 tinctive skin lesions reflective of vascular drop out.

10 who experienced sedation were more likely to drop out.

11 the use of motivational strategies to reduce drop-out.

12 ed with negative consequences such as school drop-out.

13 es as homozygotes when one of the two copies drops out.

14 d immunodeficiency syndrome or died, and 173 dropped out.

15 mine group and 58 (50%) in the placebo group dropped out.

16 Of the 33 patients enrolled, three dropped out.

17 tron group and 53 (16%) in the placebo group dropped out.

18 ted treatment for 26 weeks, and six patients dropped out.

19 s follow-up, 93 of the 748 patients (12.43%) dropped out.

20 Five percent of patients dropped out.

21 vention, 2 were excluded due to cancer and 6 dropped out.

22 One patient in the exercise group dropped out.

23 Four patients dropped out 1 year after start of treatment.

24 s will be randomized (alpha 0.05, power 90%, drop-out 10%).

25 Three patients dropped out (2 who underwent breast reconstruction [1 in

26 In total, 162 patients dropped out (20.7%), all from Group BDLT (P < 0.0001).

27 Four patients dropped out (36%) and four patients died (36%) during fo

28 Fifty-four women dropped out; 398 were included in the full analysis.

29 analysis that imputed data for patients who dropped out, 65.0% (95% CI, 51.6% to 76.9%) of the TwHF

30 patients were listed for LT (group LLT); 26 dropped-out (7.1%), 340 finally underwent PLT (group PLT

31 to hospital than were those assigned to IPS (drop-out 70 [45%] vs 20 [13%]; difference -32.1% [95% CI

32 % (24/240) did not remit, and 28.3% (68/240) dropped out; 70% (169/240) met response criteria.

33 One patient with Sezary syndrome dropped out after 1 week for personal reasons.

34 Six patients dropped out after 12 months of PFD.

35 ediately, 59% dropped out by week 12, and 7% dropped out after 12 weeks.

36 Thirty participants dropped out after assignment to 3 experimental groups; 9

37 The highest percentage of potential donors dropped out after completing the intake form, primarily

38 g protocol, and an additional three patients dropped out after the imaging session at completion of 1

39 ernatively, censoring of follow-up data (ie, dropping out) after selective crossover.

40 ost-transplant mortality and transplant list drop out and explored predictors of early transplant eva

41 ects included those participants who did not drop out and had evaluable outcome and cost data at 12 w

42 gical problems; for example, higher rates of drop out and of repeated participation.

43 PM treatment protected against capillary drop-out and limited laminin protein upregulation and EC

44 on to incorporating a probability of allelic drop-out and other critical parameters, Lab Retriever co

45 ability and is used to implement a recurrent drop-out and pattern recognition of 27 optical pulse pat

46 otal, 199 patients were enrolled, of whom 62 dropped out and 131 underwent transplantation at our ins

47 Twenty-four patients (27.3%) dropped out and 64 (72.7%) patients were transplanted.

48 Two participants dropped out and did not initiate long-acting injectable

49 up and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group a

50 eria that were undetected at entry, 8 (7.5%) dropped out, and 7 (6.5%) were removed for clinical reas

51 Three patients dropped out, and final analyses were performed on 20 com

52 We demonstrate that Hb and drop-out are mainly a function of stochastic effect of p

53 For patients who drop out because of the side-effects of oral administrat

54 Two patients in the 20 mg/day group dropped out because of adverse effects, but the other do

55 Four DHEA and one placebo group patient dropped out because of adverse effects.

56 NOS T2 treated during the study period, 5.2% dropped out because of disease progression.

57 n dropped out because of pregnancy, 23 women dropped out because of other reasons, and 27 women compl

58 Seven women dropped out because of pregnancy, 23 women dropped out b

59 had congestive heart failure; three patients dropped out because of significant asymptomatic LVEF dec

60 Six patients died, and 2 patients dropped out because they were not willing to continue th

61 bazam (n=23); two children assigned clobazam dropped out before 6 months and were excluded from the i

62 follow-up, 11 completed >=4 years, and three dropped out before 8 years.

63 e group and 33 subjects in the placebo group dropped out before completing the study.

64 Seventy-one patients dropped out before liver transplantation (rate, 11.5% in

65 apy group, and 11 (20%) in the control group dropped out before or during therapy.

66 asons and 3 cases by inevitable reasons were dropped out before pollen.

67 before study termination (including one who dropped out before receiving study treatment), and 139 (

68 one group and three in the comparator group) dropped out before receiving their study drug.

69 nded at least one postbaseline visit but who dropped out before the 12-week visit).

70 Five patients dropped out before the 18-week followup visit.

71 se of study treatment; data for patients who dropped out before the end of the study were carried for

72 ents completed all study visits except 1 who dropped out before the last visit.

73 24 did not receive the programme, and three dropped out before the trial started.

74 ticipants across all psychosocial treatments dropped out before treatment completion compared to 44.6

75 was associated with increased likelihood of dropping out before time 2 (odds ratio, 2.89; 95% CI, 1.

76 One patient in each group dropped out but data were included in analyses.

77 cluded all participants, including those who dropped out, but excluded those who did not provide outc

78 Of these, 34% dropped out immediately, 59% dropped out by week 12, and 7% dropped out after 12 week

79 overall treatment failure rate (relapse and dropping out combined) was significantly lower for cogni

80 in the highest quartile of baseline spending dropped out compared with the lowest quartile (56 of 60

81 icle, we present a novel single-cell RNA-seq drop-out correction (scDoc) method, imputing drop-out ev

82 Arteries were also examined for signal drop-out (dephasing) on phase-contrast angiograms; depha

83 d for oGTTs at 15-month intervals until they dropped out, developed diabetes, or reached 12 years pos

84 the drop-out rate was 30%, but subjects who dropped out did not differ from those who completed the

85 Here we show that mutations in drop out (dop) disturb the segregation of membrane corti

86 Drop-out due to any cause or adverse events did not diff

87 patient withdrew consent and seven patients dropped out due to cooperation difficulties under microp

88 During the study period, 172 patients dropped out due to HCC progression.

89 those, 37 (21.5%), 74 (43%), and 61 (35.5%) dropped out due to LAD, EHD, and MVI, respectively.

90 No patients dropped out due to operation before an end-point was rea

91 he waiting list, 3 of 52 patients (5.8%) had dropped out due to tumor progression.

92 Additionally, an increased risk of dropping out due to adverse events was found for diclofe

93 66 patients dropped out during phase one.

94 Three patients dropped out during the course of 8 years.

95 total of 17.2% (n = 138) of the participants dropped out during the protocol.

96 tient withdrew after randomisation and seven dropped out during the study.

97 l of 132 patients were recruited, 2 of which dropped out early in the study, leaving 130 patients who

98 f the constructs tested, the gene III and AP drop-out efficiency was between 90% and 100%.

99 ording to the predicted risk of dropout, and drop-out equivalent MELD (deMELD) points were calculated

100 , scRNA-seq data has characteristics such as drop-out events and low library sizes.

101 drop-out correction (scDoc) method, imputing drop-out events by borrowing information for the same ge

102 r challenge is how to deal with the frequent drop-out events.

103 ge to scRNA-seq research is the presence of 'drop-out' events, which usually is due to extremely low

104 olled 49 participants and analyzed 47 due to drop-out/exclusion (26 males, 40 with traumatic brain in

105 Through a community drop-out experiment, we demonstrated that in the absence

106 asons and 3 cases by inevitable reasons were dropped out for 2 years.

107 ipation after randomisation and two patients dropped out for administrative reasons.

108 candidates underwent LT, whereas 68 (11.7%) dropped-out for tumor progression.

109 term (52 weeks)),acceptability (participants dropping out for any reason), and tolerability (particip

110 Patients with low adherence tended to drop out from the system at visit 1.

111 ovides better tumor control and could reduce drop-out from transplant waitlists.

112 Seventy patients completed the trial (3 dropped out from the placebo group and 2 from the FMT gr

113 continued, 37 ended under management, and 63 dropped out from this system.

114 sed significantly and the number of patients dropping out from the waiting list because of advanced s

115 Individuals with AUD who relapsed (and dropped out) had significantly lower V(T) than those who

116 Of these, 34% dropped out immediately, 59% dropped out by week 12, and

117 ty estimation, which is crucial in scRNA-seq drop-out imputation but has not been appropriately exami

118 The higher risk of drop out in patients outside Milan, and even within Mila

119 73 patients; P=0.092), likely owing to early drop out in the MTX group.

120 omized in each treatment arm, and 2 patients dropped out in both treatment arms.

121 ty-three participants completed the study (4 dropped out in drug group).

122 per-protocol analysis, except for those who dropped out in the per-protocol analysis.

123 c is the first method that directly involves drop-out information to accounting for cell-to-cell simi

124 les are correctly called and allelic drop-in/drop-out is not observed.

125 al of 76 participants were randomized, but 2 dropped out, leaving 74 adults (43 women [58%]; mean [SD

126 A novel drop-out linker scheme was used to rapidly assess three-

127 In the IBR group, 18 patients dropped out mainly due to their aversion to implant use

128 ep biochemical fractionation procedure and a drop-out mass spectrometry approach, we show that a prev

129 Differential drop out may however cloud interpretation of data.

130 did not differ significantly from those who dropped out (n = 9) on gender, race, age, MD, or baselin

131 Finally, a machine learning model using a drop-out neural network (DONN) was employed to establish

132 ion from unselective to selective as neurons drop out of and drop into engrams; inhibitory activity d

133 However, many people drop out of educational programs, such as community coll

134 arch on this population, including those who drop out of or never access health services, is needed t

135 Neuropathy can be so disabling that patients drop out of potentially curative therapy, negatively imp

136 es more likely than nondepressed patients to drop out of prolonged exposure therapy.

137 more likely to have mental health problems, drop out of school, and become pregnant.

138 vessel tortuosity at 2-month follow-up, with drop out of small abnormal vessels and straightening of

139 bunit of this enzyme cause photoreceptors to drop out of the eye disc epithelium and move toward and

140 ecYEG by SecA and inserted, but subsequently drop out of the membrane into the cytoplasm.

141 l services were significantly more likely to drop out of the service and to be readmitted to hospital

142 raphy angiography (OCTA), showed a capillary drop out of the superficial capillary plexus and the cor

143 s where some patients will be more likely to drop out of the waitlist than receive a transplant.

144 Subjects receiving DBT were less likely to drop out of treatment (hazard ratio, 3.2; P < .001) and

145 imize self-report of suicidal ideation or to drop out of trials.

146 rticipants were significantly less likely to drop out of WET compared with PE (11 [12.5%] vs 32 [35.6

147 e, expressibility and quality of meibum, and drop-out of meibomian glands.

148 associations with the expressibility and the drop-out of meibomian glands.

149 ity of primer editing to robustly rescue the drop-out of taxa with 16S rRNA gene-targeting primer mis

150 ma Prevention Study relates to the selective drop-out of treated and untreated patients with higher i

151 Fewer patients dropped out of combined treatment vs ADM treatment alone

152 Fifty of 170 participants (29.4%) dropped out of follow-up by 5 years.

153 sleepwalking, treated with benzodiazepines, dropped out of follow-up testing and reported persistenc

154 participants (13.0%) in MORE plus usual care dropped out of MT.

155 For individuals who had already dropped out of school at baseline, we detected no signif

156 Repeating a school year or having ever dropped out of school was not more common among children

157 the exclusion of vulnerable adolescents who dropped out of school, and reporting bias due to stigma

158 Overall, 26% of enrolled patients dropped out of the acute phase treatment for nonmedical

159 e proportion of patients who responded to or dropped out of the allocated treatment.

160 he progeny of binucleate cells progressively dropped out of the cell cycle and expressed p53/p21, and

161 Four participants (5.1%) dropped out of the EMDR group, and 16 (20.3%) were early

162 Of patients who started treatment, 10 (8%) dropped out of the escitalopram group and none from the

163 trial, 12 (9.9%) and 15 (12.6%) participants dropped out of the high-fiber and AHA diet groups, respe

164 1%) who started vaccination prior to the war dropped out of the immunization program.

165 t percent of the cohort experienced death or dropped out of the list due to medical condition deterio

166 We assessed patients who dropped out of the liver transplant waiting list between

167 roup underwent emergency surgery (5 vs 1) or dropped out of the program (3 vs 1) compared to standard

168 The number of participants who dropped out of the studies because of adverse events was

169 195 of 508 of patients (38%) dropped out of the study (28% in strategy 4 vs. 40% to 4

170 82 patients dropped out of the study because of adverse events, with

171 Three subjects dropped out of the study because they were apprehensive

172 randomized to intensive lifestyle group, 31 dropped out of the study before conception.

173 n randomized to standard lifestyle group, 40 dropped out of the study before conception; among 188 wo

174 nto the COMB and 50 to the PRED treatment; 1 dropped out of the study before randomization.

175 s of study compliance, although patients who dropped out of the study before receiving the study inte

176 Five participants dropped out of the study due to adverse events.

177 Thirty participants dropped out of the study prematurely, 22 in the nefazodo

178 ears, 36.2% of the original participants had dropped out of the study, and 30.9% had not yet reached

179 in the early patching group were excluded or dropped out of the study, mostly due to loss to follow-u

180 ntinued to have disease remission, and 22.1% dropped out of the study.

181 isease remission at the study end, and 16.8% dropped out of the study.

182 At day 10, three women had dropped out of the study.

183 nt groups; 23 of these patients subsequently dropped out of the study.

184 No clusters dropped out of the study.

185 roup, and 17 out of 80 in the combined group dropped out of the study.

186 66 (21%) participants dropped out of the study.

187 Subsequently, 5 patients dropped out of the study.

188 Ten patients dropped out of the transfusion group, and two patients c

189 Follow-up lasted 3 months and one infant dropped out of the trial before commencement of treatmen

190 cations, tear film factors, and QST metrics) dropped out of these models.

191 Significantly more patients dropped out of treatment with imipramine than with fluox

192 Of the 127 participants randomized, 7 (5.5%) dropped out of treatment.

193 The impact on the proportion of children who dropped out of vaccination services after receiving 1 do

194 reduction in the proportion of children who dropped out of vaccination services.

195 rning model to identify patients at risk for dropping out of care in an urban HIV care clinic using e

196 association is driven by depressed persons' dropping out of religious activities is not clear.

197 ance use (>84%), depressive symptoms (>32%), dropping out of school (>57%), and residential instabili

198 rimAge beta = 2.430, SE = 0.761, p < 0.001), dropping out of school (GrimAge beta = 2.869, SE = 0.405

199 .21) more likely than men and boys to report dropping out of school for reasons other than school clo

200 n a broad spectrum of measures, ranging from dropping out of school to experiencing disability in one

201 child and midlife development (e.g., low IQ, dropping out of school, poor mental health, and being pa

202 diagnosed with metastatic PDAC 4 years after dropping out of surveillance.

203 held true despite more severely ill patients dropping out of the study in the usual-detection area.

204 y race between patients completing and those dropping out of the study.

205 ients either experiencing disease relapse or dropping out of the study.

206 mine patterns and predictors associated with dropping out of treatment.

207 reatment outcomes but not with more patients dropping out of treatment.

208 Surprisingly, the DNA drops out of the binding cleft with a total loss of base

209 h measured and unmeasured); participants who drop out or die are excluded from the analysis, introduc

210 fluoxetine group and 21 in the placebo group dropped out or did not complete treatment.

211 103 families dropped out or were lost to follow up.

212 No patients dropped out or were lost to follow-up in study 1; in stu

213 lacebo group and one in the pitrakinra group dropped out or were lost to follow-up.

214 26 (0.3%) individuals dropped out or were lost to follow-up.

215 at are unique to this kind of data including drop-out (or technical zeros).

216 ul improvement were reduced for patients who dropped out (OR, 0.15; 95% CI, 0.11-0.20) and had greate

217 patients do not respond to them, prematurely drop out, or never initiate treatment.

218 following revascularization or until death, drop out, or the 2016-2017 interview wave.

219 setron; one patient in the ondansetron group dropped out owing to accidental injury.

220 atment, and 3 participants in each treatment dropped out owing to serious adverse events.

221 any reason), and tolerability (participants dropping out owing to any side effects).

222 balance (Hb) and the probability of allelic drop-out p(D).

223 the transfer process, we have constructed a "drop-out" phagemid vector that can be rapidly converted

224 Eighty-seven were randomized and 26 dropped out postenrollment.

225 The results are limited by an important drop out rate.

226 e recruited of whom 103 completed the study (drop-out rate 20.8%).

227 recruited, of whom 103 completed the study (drop-out rate 20.8%).

228 ally, there was no significant difference in drop-out rate [odds ratio (OR) = 1.679, p = 0.260] or ra

229 An 11.5% drop-out rate after 3.5 months of therapy indicates the

230 However, the trial was limited by a high drop-out rate and longer-term effects of the drug requir

231 The difference in the drop-out rate between groups was mainly due to a greater

232 The median DTP1-DTP3 drop-out rate was 14%, which equates to an additional 12

233 ng subjects with longitudinal follow-up, the drop-out rate was 30%, but subjects who dropped out did

234 The drop-out rate was highest at visit 1 (9%).

235 dropped out (x(2): 26.053, p=0.016), and the drop-out rate was significantly higher at visit 1.

236 from January 2022 to April 2023, with a 3.6% drop-out rate.

237 cts and the 64 mg arm a significantly higher drop-out rate.

238 Annualized cancer detection and drop-out rates were also approximated based on the obser

239 Drop-out rates were similar in the sertraline/placebo vs

240 Limitations of the evidence include high drop-out rates, consistent with advanced cancer, as well

241 cipants in order to counter the risk of high drop-out rates.

242 As All2 allows for considering dropped-out regions, it is applicable to whole genome an

243 reatment while those identified as high-risk dropped out (risk score for dropout AUC = 0.81; p < 0.00

244 performed a short hairpin RNA (shRNA)-based drop-out screen to identify novel genes and pathways tha

245 Combined in vivo RNA sequencing and drop-out screening identified secreted frizzled-related

246 cross methodologies: in vitro enrichment and drop-out screening in lymphoma cells and immortalised fi

247 w through paired in vivo and in vitro CRISPR drop-out screens and pharmacological validation that the

248 Yeast colonies of different size appear on 'drop-out' selection plates with small clones consistentl

249 se who do receive assistance, more than half drop out shortly thereafter.

250 tice clinics were enrolled, but four clinics dropped out shortly after randomisation.

251 st observation carried forward for those who dropped out, showed that subjects on the low-carbohydrat

252 nome-wide approach in which we carried out a drop-out shRNA screen using a whole genome library that

253 tend to have earlier sexual debut and school drop-out, so an association might be expected.

254 ication and talk therapy were less likely to drop out than those who received single-modality treatme

255 y, we find that in almost all such settings, dropping out the basic graph statistics and training our

256 ubsequently, restriction digestion with AscI drops out the AP coding region and religation generates

257 restriction enzyme digestion with MfeI (to "drop-out" the gene III coding sequence), which generates

258 ied out in 50 Japanese adult MHD patients (1 dropped out); the primary outcome was the change in the

259 ng patients are aware of their treatment and drop out to pursue alternative therapeutic options; it i

260 was that better-performing patients might be dropping out to seek alternative treatments; a sensitivi

261 The sparse attention structure drops out uninformative instances in each bag, achieving

262 The main reason for participant drop out was migration out of the study area.

263 ere comparable for all variables: 8 cases of drop out were found limited to SM.

264 MG atrophy and drop-out were evident in both upper and lower eyelids of

265 dropped out within two visit, those who had dropped out were significantly younger (p=0.0067) and th

266 The reasons for dropping out were low adherence, older age, and mild sym

267 omatin, 2) statistical modeling of technical drop-out with zero-inflated methods, 3) mitigation of fa

268 Twenty percent of subjects dropped out, with half (10% of the overall group) due to

269 patients were enrolled in the trial, and 22 dropped out within 4 months.

270 s who continued, ended under management, and dropped out within two visit, those who had dropped out

271 ts who continued, ended under management, or dropped out (x(2): 26.053, p=0.016), and the drop-out ra